Stephens Consulting LLC Grows Stock Position in Novo Nordisk A/S (NYSE:NVO)

Stephens Consulting LLC boosted its stake in shares of Novo Nordisk A/S (NYSE:NVOFree Report) by 2,325.6% in the 1st quarter, HoldingsChannel reports. The fund owned 2,086 shares of the company’s stock after buying an additional 2,000 shares during the quarter. Stephens Consulting LLC’s holdings in Novo Nordisk A/S were worth $268,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also bought and sold shares of the stock. Pacific Center for Financial Services boosted its holdings in shares of Novo Nordisk A/S by 100.0% during the third quarter. Pacific Center for Financial Services now owns 270 shares of the company’s stock worth $25,000 after purchasing an additional 135 shares during the period. First PREMIER Bank purchased a new stake in Novo Nordisk A/S in the 1st quarter worth approximately $25,000. CNB Bank bought a new stake in shares of Novo Nordisk A/S in the 4th quarter worth approximately $26,000. Tyler Stone Wealth Management increased its stake in shares of Novo Nordisk A/S by 100.0% during the third quarter. Tyler Stone Wealth Management now owns 292 shares of the company’s stock valued at $27,000 after buying an additional 146 shares during the period. Finally, West Paces Advisors Inc. raised its holdings in shares of Novo Nordisk A/S by 100.0% during the third quarter. West Paces Advisors Inc. now owns 300 shares of the company’s stock valued at $27,000 after acquiring an additional 150 shares in the last quarter. 11.54% of the stock is currently owned by institutional investors.

Novo Nordisk A/S Stock Performance

Shares of Novo Nordisk A/S stock traded down $1.75 on Friday, hitting $142.74. 2,757,544 shares of the company’s stock were exchanged, compared to its average volume of 3,502,773. The company has a debt-to-equity ratio of 0.17, a quick ratio of 0.50 and a current ratio of 0.70. The stock has a market capitalization of $640.55 billion, a PE ratio of 49.22, a PEG ratio of 1.42 and a beta of 0.41. Novo Nordisk A/S has a 1 year low of $75.56 and a 1 year high of $148.15. The company has a 50-day simple moving average of $135.00 and a 200-day simple moving average of $123.71.

Novo Nordisk A/S (NYSE:NVOGet Free Report) last announced its quarterly earnings data on Thursday, May 2nd. The company reported $0.83 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.77 by $0.06. Novo Nordisk A/S had a return on equity of 91.70% and a net margin of 36.56%. The company had revenue of $9.52 billion during the quarter, compared to the consensus estimate of $9.23 billion. As a group, equities analysts anticipate that Novo Nordisk A/S will post 3.41 EPS for the current year.

Wall Street Analyst Weigh In

Several research analysts have commented on the stock. Cantor Fitzgerald restated an “overweight” rating and issued a $160.00 price objective on shares of Novo Nordisk A/S in a report on Monday, June 17th. BMO Capital Markets reaffirmed an “outperform” rating and issued a $163.00 target price on shares of Novo Nordisk A/S in a report on Tuesday, June 25th. The Goldman Sachs Group started coverage on shares of Novo Nordisk A/S in a report on Thursday, May 30th. They set a “buy” rating and a $156.00 price target on the stock. Finally, Argus increased their target price on Novo Nordisk A/S from $125.00 to $160.00 and gave the company a “buy” rating in a research note on Monday, June 10th. Two analysts have rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, Novo Nordisk A/S has a consensus rating of “Moderate Buy” and an average price target of $145.67.

Get Our Latest Report on NVO

Novo Nordisk A/S Company Profile

(Free Report)

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.

Further Reading

Want to see what other hedge funds are holding NVO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novo Nordisk A/S (NYSE:NVOFree Report).

Institutional Ownership by Quarter for Novo Nordisk A/S (NYSE:NVO)

Receive News & Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related companies with MarketBeat.com's FREE daily email newsletter.